Search

Displaying results 9201 - 9210 of 10000 in total
  1. Drug

    INS 316

    go.drugbank.com/drugs/DB05390
    Experimental

    INS316 belongs to the family of drugs called nucleoside triphosphates.It is studied in the diagnosis of lung diseases, including lung cancer. It is selective P2y2 receptor antagonists claimed to be useful as anti-inflammatory agents.

  2. Drug

    Liposomal prostaglandin E1

    go.drugbank.com/drugs/DB05391
    Investigational

    Liposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent.

  3. Drug

    TBC-3711

    go.drugbank.com/drugs/DB05407
    Investigational

    TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.

    Categories: Endothelin A Receptor Antagonists
  4. Drug

    NCX 701

    go.drugbank.com/drugs/DB05409
    Experimental

    Nitroparacetamol (NCX-701) is a newly synthesized nitric oxide-releasing derivative of paracetamol.

  5. Drug

    NCX 1022

    go.drugbank.com/drugs/DB05410
    Experimental

    NCX is an NO-releasing derivative of hydrocortisone.

  6. Drug

    OSI-461

    go.drugbank.com/drugs/DB05415
    Investigational

    OSI-461 is a second-generation molecule belonging to a new class of drugs termed selective apoptotic anti-neoplastic drugs (SAANDs).

  7. Drug

    ADX-10061

    go.drugbank.com/drugs/DB05419
    Experimental

    ADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.

  8. Drug

    Gallium maltolate

    go.drugbank.com/drugs/DB05420
    Investigational

    Gallium maltolate is Titan’s novel oral agent in development for the potential treatment of chronic bacterial infections, bone disease and cancer.

  9. Drug

    OPC-14523

    go.drugbank.com/drugs/DB05422
    Experimental

    OPC-14523 is an antidepressant drug developed by Otsuka America Pharmaceutical.

  10. Drug

    Motexafin gadolinium

    go.drugbank.com/drugs/DB05428
    Investigational

    Motexafin gadolinium is studied in the treatment of cancer by Pharmacyclics. It may make tumor cells more sensitive to radiation therapy, improve tumor images using magnetic resonance imaging (MRI), and kill cancer cells. It belongs to t...

    Categories: Compounds used in a research, industrial, or household setting